Time for Change? The Why, What and How of Promoting Innovation to Tackle Rare Diseases – Is It Time to Update the EU’s Orphan Regulation? And if so, What Should be Changed? | Citedby Results | Biomedicine Hub | Karger Publishers

Skip to Main Content

Skip Nav Destination

Time for Change? The Why, What and How of Promoting Innovation to Tackle Rare Diseases – Is It Time to Update the EU’s Orphan Regulation? And if so, What Should be Changed?

Biomed Hub (2020) 5 (2): 1–11.

This article has been cited by the following articles in journals that are participating in CrossRef Cited-by Linking.

Unmet medical needs definition and incentives: stakeholders perspectives on the reform of the EU pharmaceutical legislation

Io Wens
Zilke Claessens
Alice Vanneste
Liese Barbier
Rosanne Janssens
Isabelle Huys

Frontiers in Medicine (2025) 11

Reforming the innovation system to deliver affordable medicines: a conceptual framework of pharmaceutical innovation as a complex adaptive system (forest) and theory of change

Suerie Moon
Adrian Alonso Ruiz
Marcela C. F. Vieira
Kaitlin E. Large
Iulia Slovenski

Journal of Pharmaceutical Policy and Practice (2025) 18 (1)

Project SATURN– a real-world evidence data collaboration with existing European datasets in Osteogenesis Imperfecta to support future therapies

L. Sangiorgi
M. Boarini
I. Westerheim
R. T. Skarberg
J. Clancy
V. Wang
M. Mordenti

Orphanet Journal of Rare Diseases (2024) 19 (1)

Pharmaceutical policy and innovation for rare diseases: A narrative review

Adrián Alonso Ruiz
Kaitlin Large
Suerie Moon
Marcela Vieira

F1000Research (2023) 12: 211.

Pharmaceutical policy and innovation for rare diseases: A narrative review

Adrián Alonso Ruiz
Kaitlin Large
Suerie Moon
Marcela Vieira

F1000Research (2023) 12: 211.

Investigation of the diagnostic importance and accuracy of CT in the chest compared to the RT-PCR test for suspected COVID-19 patients in Jordan

Haytham Alewaidat
Ziad Bataineh
Mohammad Bani-Ahmad
Manar Alali
Ali Almakhadmeh

F1000Research (2023) 12: 741.

Making Sure That Orphan Incentives Tip the Right Way in Europe

Denis Horgan
Jasmina Koeva-Balabanova
Ettore Capoluongo
Beata Jagielska
Ivana Cattaneo
Marta Kozaric
Birute Tumiene
Jean-Paul El Ahl
Jonathan A. Lal
Dipak Kalra
Núria Malats

Healthcare (2022) 10 (9): 1600.

Towards Better Pharmaceutical Provision in Europe—Who Decides the Future?

Denis Horgan
Tanja Spanic
Kathi Apostolidis
Giuseppe Curigliano
Joanna Chorostowska-Wynimko
Hans-Peter Dauben
Jonathan A. Lal
Rafal Dziadziuszko
Christine Mayer-Nicolai
Marta Kozaric
Bengt Jönsson
Iñaki Gutierrez-Ibarluzea
Marie-Helene Fandel
Ruth Lopert

Healthcare (2022) 10 (8): 1594.

Meeting the Need for a Discussion of Unmet Medical Need

Denis Horgan
Bettina Borisch
Bogi Eliasen
Peter Kapitein
Andrew V. Biankin
Stefan Gijssels
Michael Zaiac
Marie-Helene Fandel
Jonathan A. Lal
Marta Kozaric
Barbara Moss
Ruggero De Maria
Marius Geanta
Frédérique Nowak
Antoni Montserrat-Moliner
Olaf Riess

Healthcare (2022) 10 (8): 1578.